KRYS
Krystal Biotech Delivers Strong Q2 Performance, Advances Pipeline and Commercial Growth
Krystal Biotech, a biotechnology company specializing in rare and serious diseases, has announced impressive results for its second quarter of 2026. In a recent conference call, the company's leadership highlighted significant progress across both commercial and clinical programs. The key takeaway from Q2 is that Krystal Biotech made